These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 26545398)
1. Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer. Ren S; Shao Y; Zhao X; Hong CS; Wang F; Lu X; Li J; Ye G; Yan M; Zhuang Z; Xu C; Xu G; Sun Y Mol Cell Proteomics; 2016 Jan; 15(1):154-63. PubMed ID: 26545398 [TBL] [Abstract][Full Text] [Related]
2. Association between bivariate expression of key oncogenes and metabolic phenotypes of patients with prostate cancer. Khodayari Moez E; Pyne S; Dinu I Comput Biol Med; 2018 Dec; 103():55-63. PubMed ID: 30340213 [TBL] [Abstract][Full Text] [Related]
3. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer. Meller S; Meyer HA; Bethan B; Dietrich D; Maldonado SG; Lein M; Montani M; Reszka R; Schatz P; Peter E; Stephan C; Jung K; Kamlage B; Kristiansen G Oncotarget; 2016 Jan; 7(2):1421-38. PubMed ID: 26623558 [TBL] [Abstract][Full Text] [Related]
4. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer. Li J; Ren S; Piao HL; Wang F; Yin P; Xu C; Lu X; Ye G; Shao Y; Yan M; Zhao X; Sun Y; Xu G Sci Rep; 2016 Feb; 6():20984. PubMed ID: 26865432 [TBL] [Abstract][Full Text] [Related]
5. Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer. Shao Y; Ye G; Ren S; Piao HL; Zhao X; Lu X; Wang F; Ma W; Li J; Yin P; Xia T; Xu C; Yu JJ; Sun Y; Xu G Int J Cancer; 2018 Jul; 143(2):396-407. PubMed ID: 29441565 [TBL] [Abstract][Full Text] [Related]
6. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score. Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743 [TBL] [Abstract][Full Text] [Related]
7. Identification of the perturbed metabolic pathways associating with prostate cancer cells and anticancer affects of obacunone. Xie J; Zhang AH; Qiu S; Zhang TL; Li XN; Yan GL; Sun H; Liu L; Wang XJ J Proteomics; 2019 Aug; 206():103447. PubMed ID: 31326558 [TBL] [Abstract][Full Text] [Related]
9. Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer. Heni M; Hennenlotter J; Scharpf M; Lutz SZ; Schwentner C; Todenhöfer T; Schilling D; Kühs U; Gerber V; Machicao F; Staiger H; Häring HU; Stenzl A PLoS One; 2012; 7(12):e50953. PubMed ID: 23251408 [TBL] [Abstract][Full Text] [Related]
10. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Weng J; Wang J; Cai Y; Stafford LJ; Mitchell D; Ittmann M; Liu M Int J Cancer; 2005 Feb; 113(5):811-8. PubMed ID: 15499628 [TBL] [Abstract][Full Text] [Related]
11. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582 [TBL] [Abstract][Full Text] [Related]
12. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749 [TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763 [TBL] [Abstract][Full Text] [Related]
15. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Varambally S; Laxman B; Mehra R; Cao Q; Dhanasekaran SM; Tomlins SA; Granger J; Vellaichamy A; Sreekumar A; Yu J; Gu W; Shen R; Ghosh D; Wright LM; Kladney RD; Kuefer R; Rubin MA; Fimmel CJ; Chinnaiyan AM Neoplasia; 2008 Nov; 10(11):1285-94. PubMed ID: 18953438 [TBL] [Abstract][Full Text] [Related]
16. Prostate cancer-associated gene expression alterations determined from needle biopsies. Qian DZ; Huang CY; O'Brien CA; Coleman IM; Garzotto M; True LD; Higano CS; Vessella R; Lange PH; Nelson PS; Beer TM Clin Cancer Res; 2009 May; 15(9):3135-42. PubMed ID: 19366833 [TBL] [Abstract][Full Text] [Related]
17. Tissue-based metabolomics reveals metabolic signatures and major metabolic pathways of gastric cancer with help of transcriptomic data from TCGA. Wang Y; Chen W; Li K; Wu G; Zhang W; Ma P; Feng S Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34549263 [TBL] [Abstract][Full Text] [Related]